ALT Q4 2025 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$353M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26,000+420.0% YoY

Gross Profit

$00.0% margin

Operating Income

-$29M-111126.9% margin

Net Income

-$27M-105223.1% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

+420.0%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$280M

Total Liabilities

$55M

Stockholders' Equity

$225M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26,000	$5,000	+420.0%
Gross Profit	$0	$5,000	-100.0%
Operating Income	-$29M	-$25M	-16.2%
Net Income	-$27M	-$23M	-18.0%